Prospective Validation of Machine Learning Model to Predict Platinum Induced Nephrotoxicity in Cancer Patients

Launched by TAIPEI MEDICAL UNIVERSITY · Aug 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict kidney problems caused by certain chemotherapy drugs called platinum-based drugs, which are commonly used to treat cancer. The researchers want to see if a computer program (using machine learning) can better predict who might develop kidney damage compared to doctors’ usual methods. The study focuses on cancer patients in Taiwan who receive treatments like Cisplatin or Carboplatin, which can sometimes affect kidney health.

If you join the study, you need to be between 20 and 89 years old, have a cancer diagnosis, and be starting treatment with these platinum-based chemotherapy drugs. You’ll have blood tests before and after your treatment to check how your kidneys are working. The study will also ask for a small DNA sample to help improve the predictions. Over time, the doctors will closely watch your kidney function to see if any problems develop. This information will help make treatments safer for future patients by identifying those at higher risk of kidney issues early on.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients under clinical diagnosis of cancer with treatments including at least taking one course treatment of Cisplatin and Carboplatin from Dec,2022 to July,2026, at least having one serum creatinine data before and after the administration, willing to provide DNA sample and sign the informed consent will be recruited.
• Exclusion Criteria:
• • Patients who are young than 20 years old or older than 89 years old, pregnant women, infected by Human Immunodeficiency Virus (HIV), administered by Ifosfamide, couldn't evaluate their kidney function, refuse to provide DNA sample and sign the informed consent will be excluded.